The Gastroenteropancreatic Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of GEP-NETs with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Gastroenteropancreatic Neuroendocrine Tumors Treatment.
GEP-NETs key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
GEP-NETs Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the GEP-NETs market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Various Key players such as ITM Isotopen Technologien Muenchen (ITM), EpicentRx, and others are in the process of developing potential therapies for the treatment of Gastroenteropancreatic Neuroendocrine Tumour.
Gastroenteropancreatic Neuroendocrine Tumors Therapies covered in the report include:
Solucin (n.c.a. 177Lu-Edotreotide / n.c.a. 177Lu-DOTATOC)
And many more.
The launch of emerging products will significantly impact the Gastroenteropancreatic Neuroendocrine Tumour market in the coming years.
Request for Sample Pages @ Gastroenteropancreatic Neuroendocrine Tumors Emerging Therapies and Key Companies
Table of Content
1. Report Introduction
2. Gastroenteropancreatic Neuroendocrine Tumors
3. Gastroenteropancreatic Neuroendocrine Tumors Current Treatment Patterns
4. Gastroenteropancreatic Neuroendocrine Tumors – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Gastroenteropancreatic Neuroendocrine Tumors Late Stage Products (Phase-III)
7. Gastroenteropancreatic Neuroendocrine Tumors Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastroenteropancreatic Neuroendocrine Tumors Discontinued Products
13. Gastroenteropancreatic Neuroendocrine Tumors Product Profiles
14. Gastroenteropancreatic Neuroendocrine Tumors Key Companies
15. Gastroenteropancreatic Neuroendocrine Tumors Key Products
16. Dormant and Discontinued Products
17. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs
18. Gastroenteropancreatic Neuroendocrine Tumors Future Perspectives
19. Gastroenteropancreatic Neuroendocrine Tumors Analyst Review
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States